[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366512-105":59,"doc-detail-366512-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","pyroptosis-mediator-gsdmd-in-plasma-a-potent-biomarker-for-lung-cancer-diagnosis-and-prognosis-assessment","Pyroptosis-Mediator GSDMD in Plasma - A Potent Biomarker for Lung Cancer Diagnosis and Prognosis Assessment","","Lung cancer’s high mortality is driven by delayed detection, and current diagnostic approaches show limited accuracy. This study assessed Gasdermin D (GSDMD) in lung cancer and investigated its biological and clinical relevance. Among 114 patients with lung cancer, 87 with pulmonary nodules, and 100 healthy controls, plasma GSDMD was measured alongside established tumor markers and analyzed with statistical and logistic regression methods. Results indicated strong association and ROC performance, supporting GSDMD as a diagnostic and prognostic biomarker, alone or combined with other markers.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pyroptosis-mediator-gsdmd-in-plasma-a-potent-biomarker-for-lung-cancer-diagnosis-and-prognosis-assessment/366512/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pyroptosis-mediator-gsdmd-in-plasma-a-potent-biomarker-for-lung-cancer-diagnosis-and-prognosis-assessment/366512.png","ImageObject",300,407,{"name":92,"@type":93},"Aran","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the objective of this study on GSDMD in lung cancer?","Question",{"text":112,"@type":113},"To evaluate the diagnostic efficacy of Gasdermin D (GSDMD) for lung cancer and explore its biological functions while addressing limitations of current methods.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which groups were included and what was measured?",{"text":117,"@type":113},"The study enrolled lung cancer patients, patients with pulmonary nodules, and healthy controls, measuring plasma GSDMD and multiple tumor markers using specific assays.",{"name":119,"@type":110,"acceptedAnswer":120},"How accurate was plasma GSDMD for diagnosing lung cancer?",{"text":121,"@type":113},"Plasma GSDMD achieved an AUC of 0.860, with a cut-off value of 39.87 pg/mL yielding 95.6% sensitivity and 72.2% specificity.",{"name":123,"@type":110,"acceptedAnswer":124},"Did combining GSDMD with other biomarkers improve performance?",{"text":125,"@type":113},"Yes. When combined with CEA, SCC, and HE4, the AUC increased to 0.959, with 93.0% sensitivity and 82.9% specificity.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},366512,1790203001,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},137455076865,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","International Journal of General Medicine  \n Open Access Full Text Article  \nORIGINAL RESEARCH  \nPyroptosis-Mediator GSDMD in Plasma: A Potent Biomarker Lung Cancer Diagnosis and Prognosis Assessment  \nXuexin Liu , Fang Yu, Nan Ding , Changmei Wei, Yuhui Cui, Lijing Huo  Department of Medical Laboratory, Hebei General Hospital, Shijiazhuang, Hebei, People’s Republic of China  \nCorrespondence: Lijing Huo, Department of Medical Laboratory, Hebei General Hospital, 348 Heping West Road, Xinhua District, Shijiazhuang, Hebei, People’s Republic of China, Email [huolijing1979@126.com](huolijing1979@126.com)  \n\n| Objective: Lung cancer’s high mortality is linked to late diagnosis, with current methods having limitations. This study aimed to evaluate the diagnostic efficacy of Gasdermin D (GSDMD) in lung cancer and explore its biological functions.\u003Cbr>Methods: A total of 114 lung cancer patients, 87 patients with pulmonary nodules, and 100 healthy controls were enrolled. Clinical data were collected, and venous blood samples were obtained. GSDMD, carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), cytokeratin 19 fragment (CYFRA21-1), and other markers were measured using specific assays. Statistical analysis, including variance tests, ANOVA, and logistic regression, was performed to analyze the data.\u003Cbr>Results: There were no significant differences in age and gender among the three groups. However, GSDMD levels were highest in the lung cancer group, followed by the pulmonary nodule group, and lowest in the healthy control group (P \u003C 0.05) . GSDMD was positively correlated with multiple biomarkers such as CEA (r = 0.329, P \u003C 0.001), NSE (r = 0.266, P \u003C 0.001), and CYFRA21-1 (r = 0.477, P \u003C 0.001) . Multivariate logistic regression analysis indicated that serum GSDMD, CEA, SCC, HE4, and IL - 6 were independent risk factors for lung cancer. The area under the ROC curve (AUC) of plasma GSDMD was 0.860, higher than that of CEA (0.801) and SCC (0.843) . At a plasma GSDMD cut -off value of 39.87 pg/mL, the diagnostic sensitivity was 95.6%, and the specificity was 72.2% . When combined with other biomarkers (CEA, SCC, and HE4), the AUC reached 0.959, with a sensitivity of 93.0% and a specificity of 82.9% .\u003Cbr>Conclusion: GSDMD holds promise as a diagnostic/prognostic biomarker for lung cancer, alone or combined with other markers, enhancing risk assessment accuracy to aid early detection and improve outcomes.\u003Cbr>Keywords: lung cancer, gasdermin D, biomarker, diagnosis, prognosis, inflammation, tumor markers |\n| --- |\n| Introduction\u003Cbr>Lung cancer remains one of the most lethal malignancies worldwide, with a disproportionate impact on both developed and developing nations. According to GLOBOCAN 2020 data, lung cancer constitutes 11.4% of all new cancer cases and 18.0% of cancer-related deaths globally, surpassing breast and colorectal cancers in mortality burden. Lung cancer continues to be a major global health challenge, with its pathogenesis driven by a dynamic interplay of modifiable and non-modifiable risk factors. Cigarette smoking remains the predominant contributor, responsible for nearly 80–90% of cases, as highlighted by recent meta-analyses confirming the dose-dependent relationship between smoking duration andadenocarcinoma risk. Lung cancer stands as the most frequently diagnosed type of cancer and is also the primary cause of cancer-related mortality among males. Non-small cell lung cancer (NSCLC) constitutes roughly 80% of all lung cancer cases.1 Regrettably, the vast majority of patients afflicted with NSCLC are diagnosed with the carcinoma at a stage where they already have locally advanced or metastatic disease2,3.Despite advances in therapeutic strategies, the 5-year survival rate for lung cancer patients remains dismal, largely due to late-stage diagnosis exacerbated by socioeconomic disparities |\n\nReceived: 26 April 2025  \nAccepted: 15 August 2025  \nPublished: 24 August 2025  \nInternational Journal of General Med","cbCairI1cMCQVk7y","https://ap.wps.com/l/cbCairI1cMCQVk7y","pdf",4785458,11,"English","# Objective\n# Methods\n# Results\n# Conclusion\n# Introduction\n# Received, Accepted, Published","[{\"question\":\"What was the objective of this study on GSDMD in lung cancer?\",\"answer\":\"To evaluate the diagnostic efficacy of Gasdermin D (GSDMD) for lung cancer and explore its biological functions while addressing limitations of current methods.\"},{\"question\":\"Which groups were included and what was measured?\",\"answer\":\"The study enrolled lung cancer patients, patients with pulmonary nodules, and healthy controls, measuring plasma GSDMD and multiple tumor markers using specific assays.\"},{\"question\":\"How accurate was plasma GSDMD for diagnosing lung cancer?\",\"answer\":\"Plasma GSDMD achieved an AUC of 0.860, with a cut-off value of 39.87 pg/mL yielding 95.6% sensitivity and 72.2% specificity.\"},{\"question\":\"Did combining GSDMD with other biomarkers improve performance?\",\"answer\":\"Yes. When combined with CEA, SCC, and HE4, the AUC increased to 0.959, with 93.0% sensitivity and 82.9% specificity.\"}]","Pyroptosis-Mediator GSDMD in Plasma - A Potent Biomarker for Lung Cancer Diagnosis and Prognosis Assessment | PDF",1790165886,28,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3da30335089d10622b68e680e0046057.webp",983,1272,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f6cd1475c7a2523c00912d461ed17ee.webp",982,1270,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52da92f47eb39d708f02b5b9acd9681e.webp",981,1269,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f0c3c92ce686b4c3e5c4422c15c05d5b.webp",980,1268]